The group will start a pivotal trial of samuraciclib following promising second-line results.

The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.

Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.

Global phase 2 data in TNBC look similar to earlier results in China.

Studies presented at ASH show this to be true only up to a point.

Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.